Travere Therapeutics: FILSPARI Drives Revenue, FSGS PDUFA Looms [Seeking Alpha]
Travere Therapeutics, Inc. (TVTX)
Company Research
Source: Seeking Alpha
FY25 revenue grew 81% to $410.5M, driven by FILSPARI's 144% YoY growth and record patient starts, signaling robust commercial momentum. Profitability metrics improved, with 4Q25 GAAP net income positive and non-GAAP net income at $81.1M, reflecting operating leverage and cost discipline. TVTX trades at ~15x forward non-GAAP earnings, with valuation hinging on the FSGS regulatory outcome, which could significantly expand FILSPARI's addressable market. Sinhyu/iStock via Getty Images Thesis Travere Therapeutics ( TVTX reported 4Q25 non-GAAP EPS of $0.37, a figure that was mostly in line with expectations. However, revenue came in at $129.6 million, and despite it being up 73% year over year, it missed consensus by about $18 million. Overall, the stock This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this
Show less
Read more
Impact Snapshot
Event Time:
TVTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
TVTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
TVTX alerts
High impacting Travere Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
TVTX
News
- Travere Therapeutics, Inc. (TVTX): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025 [Yahoo! Finance]Yahoo! Finance
- A Look At Travere Therapeutics (TVTX) Valuation After Q4 Earnings Beat And FILSPARI Regulatory Progress [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics Inc (TVTX) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]Yahoo! Finance
- Travere Therapeutics (TVTX) Matches Q4 Earnings Estimates [Yahoo! Finance]Yahoo! Finance
TVTX
Earnings
- 2/19/26 - Beat
TVTX
Sec Filings
- 2/24/26 - Form 4
- 2/20/26 - Form 144
- 2/19/26 - Form 10-K
- TVTX's page on the SEC website